Dissecting the underlying mechanism in vitro, Fukushima et al. showed that glasdegib reduces the LSC-containing CD34+CD38− population and increases the proliferative cell fraction in patient-derived AML samples. The gene discussed is CD34; the disease is acute myeloid leukemia.